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Introduction: Approximately 80% of non-small cell lung cancer (NSCLC) patients with
bone metastases have cancer induced bone pain (CIBP).
Methods: The NVALT-9 was an open-label, single arm, phase II, multicenter study. Main
inclusion criterion: bone metastasized NSCLC patients with uncontrolled CIBP [brief pain
inventory [BPI] ≥ 5 over last 7 days]. Patients were treated with six milligram ibandronate
intravenously (day 1–3) once a day. Main exclusion criteria: active secondary malignancy,
systemic anti-tumor treatment and radiotherapy ≤4 weeks before study start, previous
bisphosphonate treatment. Statistics: Simon’s Optimal two-stage design with a 90%
power to declare the treatment active if the pain response rate is ≥ 80% and 95%
confidence to declare the treatment inactive if the pain response rate is ≤ 60%. If pain
response is observed in ≤12 of the first 19 patients further enrollment will be stopped.
Primary endpoint: bone pain response, defined as 25% decrease in worst pain score
(PSc) over a 3-day period (day 5–7) compared to baseline PSc with maximum of 25%
increase in mean analgesic consumption during the same period. Secondary endpoints:
BPI score, quality of life, toxicity and World Health Organization Performance Score.
Results: Of the 19 enrolled patients in the first stage, 18 were evaluable for response.
All completed ibandronate treatment according to protocol. In 4 (22.2%), a bone pain
response was observed. According to the stopping rule, further enrollment was halted.
Discussion: Ibandronate loading doses lead to insufficient pain relief in NSCLC patients
with CIBP.
Keywords: carcinoma, non-small-cell lung, pain management, cancer induced bone pain, clinical trials, phase II
as topic, ibandronic acid
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INTRODUCTION
Cancer induced bone pain (CIBP) is an important issue in
metastasized non-small cell lung cancer (NSCLC). During the
course of the disease, 24–60% of NSCLC patients are diagnosed
with bone metastases and up to 80% will experience CIBP (1–
3). Furthermore, bone metastases have a negative influence on
quality of life (QoL) and are associated with a poorer overall
survival (OS) (4). Radiotherapy is an effective treatment for
CIBP with a 50% chance of complete pain resolution, but it
unfortunately has several drawbacks. Examples are a time delay
before the maximum treatment effect is obtained, the possibility
of a pain flare-up, and it is only feasible in patients with a limited
number of bone metastases (5). In general, pain management,
according to theWorld Health Organization (WHO) pain ladder
(6), frequently results in treatment with opioids. Especially in this
vulnerable population, opioid use can result in neurologic, renal,
hepatic, and/or gastro-intestinal toxicity (7).
In current guidelines [e.g., European Society for Medical
Oncology [ESMO], National Comprehensive Cancer Network
[NCCN], and National Institute for Health and Care Excellence
[NICE]] bone targeted agents such as bisphosphonates are
mentioned as an option to prevent skeletal related events (SREs)
in NSCLC patients (5, 8–10). However, actual data on (rapid)
pain relief of bisphosphonates are scarce in NSCLC (11). Trials
including patients with bone metastases from prostate- or breast-
or lung cancer (N = 607 of which only 1 NSCLC patient), which
evaluated the effect of ibandronate (intravenous or oral) on bone
pain showed pain relief within 7 days to 12 weeks after start
of ibandronate (12–14). Therefore, we performed a multicenter
phase II study to evaluate the effect of intravenous loading doses
of ibandronate on acute pain response in NSCLC patients with
uncontrolled CIBP.
MATERIALS AND METHODS
The primary aim of this open label single arm phase II study
(NVALT-9, EudraCT number 2007-000885-20, NTR1602) was to
establish the efficacy of intravenous loading doses of ibandronate
to achieve acute bone pain relief in NSCLC patients with CIBP.
The trial was approved by the appropriate ethics committee
(METC 07-2-035.6/ivb).
The trial was performed in eight Dutch hospitals (see
Supplementary Data, paragraph 1). The main inclusion criteria
were: (I) pathologically proven NSCLC with pathologically
and/or radiologically confirmed bone metastases with a patient
life expectancy of at least 1 month; (II) the pain scored for
bone metastases had to correspond to known locations of bone
metastases (based on imaging); (III) mean bone pain score ≥
five over the last 7 days before inclusion on the worst pain
scale on the brief pain inventory (BPI), (IV) use of non-
steroidal anti-inflammatory drugs (NSAIDs) or a weak opioid
base on the WHO analgesic ladder step 2, (V) adequate renal
function (creatinine clearance as calculated by Cockcroft-Gault
method > 50 ml/min). The main exclusion criteria were: (I)
active secondary malignancies, (II) start of anti-tumor treatment
within 4 weeks before study entry, (III) bone radiotherapy in
the preceding 4 weeks, (IV) bisphosphonate treatment in the
previous 2 months, (V) hypocalcemia (serum albumin corrected
calcium concentration < 2 mmol/L) or hypercalcemia (serum
albumin corrected calcium≥ 2.7 mmol/L).
With the aim of assessing the efficacy of ibandronate on acute
bone pain relief, the primary endpoint was acute bone pain
response over a 7-day period. This was defined as a 25% decrease
in worst bone pain score over day 5, 6, and 7 compared to bone
pain score at baseline (determined by the “worst pain scale” of
the BPI), with no more than a 25% increase in mean analgesic
consumption over the same 3-day period compared to baseline
analgesic consumption. Secondary endpoints were mean worst
bone pain scale of the BPI in the first 7 days, interference scales
of the BPI, analgesic consumption, WHO-Performance Score
(WHO-PS), QoL, and safety. In the context of safety spontaneous
adverse events (scored by Common Terminology Criteria for
Adverse Events [CTCAE] version 4.0) were collected.
Patients were treated with six mg ibandronate once a day
intravenously on day one, two, and three. Concomitant analgesic
use was assessed using the WHO pain ladder. On day 1–7
patients recorded their worst bone pain score of the BPI and their
analgesic consumption in a diary. Patients were evaluated for BPI,
WHO-PS, and QoL on day 1 and 7. On day 7, a serum chemistry
panel (including serum creatinine) was performed to assess the
renal safety of ibandronate. Adverse events were recorded on day
1–3, on day 7, and at the end of follow-up (day 28).
The study was designed following a Simon’s Optimal two-
stage design with a 90% power to declare the treatment active if
the pain response rate was ≥ 80 and 95% confidence to declare
the treatment inactive if the pain response rate was ≤ 60%. The
60% pain response rate is comparable to expected response rates
of radiotherapy and opiates on cancer related pain (5, 15). In the
first stage, 19 patients were treated and evaluated. If ≤ 12 pain
responses were observed the study was stopped. Otherwise, 34
patients would subsequently be enrolled and the treatment would
be declared active if ≥38 of 53 included patients had a positive
pain response.
RESULTS
Between December 2007 and November 2010, 19 NSCLC
patients were enrolled in the first stage. Eighteen out of 19
patients were evaluable for response. The patient characteristics
are shown in Table 1. One patient received only 1 day of study
medication, as it was discovered that the patient was ineligible
because of previous bisphosphonate use. All other patients
received all doses of ibandronate without dose reductions or
dose delays. Patients were treated with analgesics according the
WHO pain ladder (6). Before study entry, four patients were
also treated with anti-epileptics and one patient with methadone
because of uncontrolled pain. Except for two patients, none
of the patients were able to reduce their analgesic use during
the study period and in two other patients, the opioid doses
increased. For the primary endpoint of bone pain response,
four out of 18 patients (22%) had a ≥25% decrease in worst
pain score over day 5–7, therefore the endpoint was not met
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TABLE 1 | Patient characteristics.
Patient characteristics N = 18
Gender, male (%) 12 (67)
Age, mean (range) 58.7 (42–74)





Prior treatment for malignancy Surgery for BM (%) 2 (11)
Chemotherapy (%) 12 (67)
Palliative radiotherapy to BM, yes (%) 5 (28)
Current analgesics (n/N) Analgesics according to WHO pain laddera 15/15
Analgesics according to WHO pain laddera + anti-epileptics 4/15
Analgesics according to WHO pain laddera + anti-epileptics + methadone 1/15
Patient status at day 28 (%) Alive 9 (64)
Patient status at day 28 for bone pain responders (%) Alive 4 (100)
WHO-PS, World Health Organization Performance Score; BM, bone metastases. aAnalgesics according to WHO pain ladder means a one to three step, which starts with non-opioids
with or without any adjuvant therapy and increases to opioids for moderate to severe pain with or without any non-opioids or adjuvant therapy.
FIGURE 1 | The observed and estimated worst pain scores for patients
grouped by outcome (no bone pain responder vs. bone pain responder). No
bone pain response is depicted by open circles (N = 14), bone pain response
is depicted by solid circles (N = 4).
and the study was discontinued. Figure 1 shows the observed
and estimated worst bone pain scores for patients grouped
by outcome.
In Table 2 primary and secondary endpoints were shown.
For secondary endpoints, two patients (11.1%) reported an
improvement of WHO-PS during treatment while 33.3 and
16.7% reported no change or a worsening of WHO-PS,
respectively. In seven patients (38.9%) change in WHO-PS was
not recorded. No relation between change in WHO-PS and
bone pain response was recorded. After 28 days follow-up 5
patients (27.8%) had died. Mean worst bone pain scale of the BPI,
interference scales of the BPI, analgesic consumption, and QoL
revealed no significant or clinically relevant differences between
study participants (see Supplementary Data, paragraph 2). No
serious adverse events were reported. Two patients experienced
≥ grade 2 hypophosphatemia (one grade 2, one grade 3), which
was possibly treatment related.
DISCUSSION
This study of intravenous loading doses of ibandronate inNSCLC
patients with CIBP did not show adequate pain reduction in
most patients. However, in four out of 18 patients a sufficient
pain response was observed. In contrast to most other trials in
which patients used concomitant anti-cancer therapy (making
evaluation of the effect of the bone targeted agent more difficult),
patients in this study were only eligible if they did not start
an anti-cancer therapy (systemic therapy and/or radiotherapy)
in the 4 weeks before study entry. To not unnecessarily expose
patients to a treatment that was not beneficial enough, a Simon
2-stage design was used, and the trial was stopped due to futility.
CIBP remains important in NSCLC. Despite these older data
of ibandronate loading dose for acute pain relief in lung cancer
patients with CIBP, no new treatment options with rapid pain
relief are currently available. Furthermore, phase II/III trials in
metastasized NSCLC evaluating systemic anti-cancer treatment
modalities (i.e., chemotherapy with or without immunotherapy
and tyrosine kinase inhibitors) are not focused on rapid bone
pain reduction and only report pain as an adverse event of
therapy. We show that loading doses of bisphosphonates do not
induce a rapid reduction of CIBP and that other strategies should
be pursued.
There is evidence of the effects of bisphosphonates on pain
reduction for breast cancer, multiple myeloma and prostate
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TABLE 2 | Primary and secondary endpoints.
Primary endpoint
Bone pain responsea N, % Yes 4 (22)
Secondary endpoint
Mean worst pain score over last













Interference scales of the BPI No significant or clinically relevant
difference between scores at day 1
compared to day 7 on all interference
scales of the BPI.
Analgesic consumption No significant or clinically relevant
difference between analgesic
consumption at day 1 compared to
day 7.
Change in WHO-Performance










Quality of Lifec No significant or clinically relevant
difference between scores at day 1
compared to day 7 on all dimensions
of QLQ-C30 questionnaire.
Spontaneous adverse events N,
%
CTCAE grade 2 hypophosphatemia 1 (6)
BPI, brief pain inventory; QLQ-C30, Quality of Life Questionnaire-Core 30; CTCAE v4.0,
Common Terminology Criteria for Adverse Events. adefinition of bone pain response: a
25% decrease in worst bone pain score over day five, six, and seven compared to bone
pain score at baseline (as determined by the “worst pain scale” of the BPI), with no more
than a 25% increase in mean analgesic consumption over the same three-day period
compared to baseline analgesic consumption. bmeasured on a scale 0–10 according to
the brief pain inventory. cscored by Quality of Life Questionnaire-Core 30 (QLQ-C30).
cancer (12–14, 16). Analogous to a previous pilot study (13), in
which opioid refractory bone pain was relieved by ibandronate
loading doses within 7 days, ibandronate was the bisphosphonate
of choice in our study. It is unclear why breast or prostate cancer
patients responded to loading doses of bisphosphonates in a
previous studies (12–14, 17, 18), while the NSCLC patients in
our study did not. There could be different explanations why
NSCLC patients in this study do not respond to bisphosphonates:
(I) Influence of tumor histology on the chance of bone pain
reduction by bisphosphonates, (II) Possible differences in the
metabolism of bone metastases between breast cancer and lung
cancer (although not shown when evaluating bone turnover
markers) (19) or (III) Lack of concomitant systemic therapy
which resulted in reduced pain control, as in a systematic
review and meta-analysis the combination of bisphosphonates
and systemic therapy was superior compared with one of the two
treatment modalities alone (20).
We observed that bone pain response was not associated
with an improvement in WHO-PS; only one of the bone
pain responding patients improved while two patients with a
reduction in pain had a deteriorating WHO-PS, probably due to
progression of cancer. Bone pain response was associated with
survival as all four patients in the bone pain responding group
were alive at study completion, whereas five of the 14 patients in
the no bone pain responding group already had died because of
progressive disease. Of all enrolled patients, 27.8% died within
1 month, although only patients with a life expectancy of more
than 1 month could be enrolled. This stresses that it is difficult
for physicians to accurately estimate the prognosis of a patient.
It is already known that physicians tend to overestimate survival
of patients in 27–42% of patients (21, 22). However, 2/3 of the
included patients in our study had a good performance status
(WHO PS 0-1), and in general this is associated with a survival
of more than 1 month (23). Compared with the literature, QoL
was lower for our patients, especially on the domains of role,
cognitive, and social functioning (24–26). It could be that the
high pain scores influenced these parts of QoL.
LIMITATIONS AND STRENGTHS
A limitation of this study is the BPI as assessment tool of bone
pain, because the BPI does not exclude pain from other causes.
To the best of our knowledge, there are no tools or questionnaires
to fully discriminate between bone pain and pain from other
causes. We attempted to minimize bias due to pain from other
causes by only including patients with bonemetastases diagnosed
by imaging studies, bone pain corresponding with a location of
bone metastases on imaging, or investigator judgment that the
reported pain was indeed caused by bone metastases. Lacking
a placebo arm is another limitation of the study. However, in
light of insufficient pain relief by ibandronate, this probably did
not have any influence on the interpretation of the results (i.e.,
low chance of placebo effect). Furthermore, we assessed changes
in WHO-PS at 7 days after ibandronate infusion. Additional
collection of WHO-PS through day 28 would have likely added
value in identifying long-term changes in performance status. A
strength of this study is the separation of systemic treatment and
treatment for CIBP as there is no potential interaction in efficacy
on rapid pain relief.
CONCLUSION
In conclusion, loading doses of ibandronate do not lead to
rapid bone pain relief in a sufficient number of NSCLC patients
with uncontrolled CIBP to constitute its use. Studies evaluating
other treatment options for rapid bone pain relief in this patient
population are necessary.
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